The sentiment remained robust in the broader markets too as the BSE Midcap touched new high in intra-day session and ended 1.31 per cent higher
Market rally has added roughly 1 percentage point to GDP growth each quarter since October-December
Large part of gains in two years accrued to top companies in metals, IT, pharma and realty
As Indian stock markets hit all-time highs, Business Standard looked at how often such winners are to be found
Its stock price up 17.3%, outperforming the index that is up 10.5%
Despite a 5,000-point surge by Sensex, overall market breadth was the worst since March 2020 when stocks had collapsed following the spread of the Covid-19 pandemic
Indian shares hit all-time highs on Wednesday, helped by financials and automaker stocks, and after data showed the economy grew more than 20% in the June-quarter
Ultra-easy monetary policy from the Reserve Bank of India was the primary domestic driver of that rally
Since the end of July, measures of red-hot small and midcap shares have slumped and just a bunch of heavyweights have been keeping the largecap rally alive
Overseas funds have poured $7.2 trillion into the nation's equities this year and net inflows are expected to continue.
Headline valuations are at 10-15 per cent premium to 10-year historical range, but are supported by the lower bond yields in comparison to what we have witnessed in the last decade, Singh said
A depreciating rupee and lacklustre global cues further weighed on sentiment, traders said
FPI flows took a hit during the quarter. However, retail buying and domestic mutual funds more than compensated
Global equities marched higher after US senators agreed on a bipartisan infrastructure deal, with investors wagering on more stimulus measures in the coming months
200 firms of the BSE 500 universe are tracked by more brokerages than a year ago
Strong first quarter could help STT mop-up surpass Budget Estimates for FY22, say govt officials
At the closing bell, the 30-share BSE index quoted 221.52 points or 0.42 per cent higher at 52,773.05
Orphazyme A/S, which develops therapies to treat genetic disorders, says it has no idea why its American depositary shares surged overnight
A sharp recovery in the rupee added to the momentum, even as lacklustre global cues capped the gains, traders said
In 2013, amid the taper tantrum sell-off, it had dropped to just $1 billion, shows an analysis done by ICICI Securities